DEA opposes additional rescheduling briefing on GAO report

DEA draws a line on another briefing

The DEA told Cannabis Wire it opposes an additional briefing on a GAO report connected to marijuana rescheduling. The outlet published the report on Oct. 14, 2026.

That's the confirmed core. Everything beyond it needs care.

What the signal doesn't tell us

The public record available so far leaves out who requested the briefing, what the GAO report found, and what the DEA's stated reasons were. The Cannabis Wire headline is the only verified element CannIntel has reviewed.

We aren't going to guess at the rest. A refusal to hold a briefing can mean scheduling conflicts, a pending legal posture, or a view that the report has already been addressed. Those are very different stories.

CannIntel has requested the underlying Cannabis Wire reporting and will update this piece when specifics are confirmed on the record.

Why a briefing fight matters to the rescheduling timeline

Even a procedural dispute over a briefing signals that the DEA and outside overseers aren't aligned on how much explanation the scheduling process owes. Rescheduling marijuana from Schedule I under the Controlled Substances Act has been a slow, litigation-prone effort.

Every friction point matters because the process has repeatedly stalled on procedure rather than substance. That pattern is hard to ignore.

Still, a declined briefing isn't a ruling. It doesn't move marijuana to Schedule III, and it doesn't stop it either.

Rescheduling doesn't rewrite the hemp definition

Hemp is defined by statute, not by the Controlled Substances Act schedules, so any outcome on marijuana scheduling leaves the hemp test untouched. The 2018 Farm Bill, codified at 7 U.S.C. 1639o, defines hemp as cannabis with a delta-9 THC concentration of not more than 0.3% on a dry weight basis.

Marijuana, by contrast, is the same plant above that line. A scheduling change would alter how the DEA treats marijuana. It wouldn't redraw the 0.3% threshold, which only Congress can change.

THCA is where the chemistry breaks the test

THCA converts to delta-9 THC through decarboxylation, which is why delta-9-only testing and total-THC testing can give opposite answers on the same flower. Heat strips a carboxyl group from THCA, releasing CO2 and leaving delta-9 THC.

The conversion isn't one-to-one by weight. THCA's molecular weight is about 358.5 g/mol against roughly 314.5 for delta-9 THC, so the theoretical yield is about 87.7% of the THCA mass. In practice, labs apply that factor when they report total THC as delta-9 plus 0.877 times THCA.

A flower sample can read under 0.3% delta-9 as sold and still deliver far more once smoked or vaped. That gap is the entire loophole fight, and it sits outside the DEA scheduling question. Whether regulators measure delta-9 alone or total THC remains the sharpest dividing line in hemp enforcement.

The operator lens: two separate tax and legal tracks

Marijuana operators and hemp-derived THC sellers face different federal exposure, so a scheduling delay hits them unevenly. Licensed marijuana businesses remain subject to Section 280E of the tax code as long as their product sits in Schedule I or II. Rescheduling to Schedule III is the path that would end that exposure.

Hemp sellers don't carry 280E risk in the same way, but they face a patchwork of state rules and shifting federal guidance on total THC. For them, the more consequential variable is Congress and state agencies, not the DEA's briefing calendar.

For full background on this story, see the CannIntel topic hub on DEA cannabis rescheduling.

What to watch next

The next useful signals are the GAO report text, the name of whoever requested the briefing, and any DEA statement explaining its opposition. Those three items would turn a headline into a story with stakes.

Watch also for whether Congress or HHS responds on the record. Until then, the picture is unsettled. Expect enforcement on THCA products to vary by state regardless of what happens in Washington.